Bjørt K. Kragesteen

Bjørt K. Kragesteen

Auto-generated profile, based on publicly available information

Bjørt K. Kragesteen

Max Planck Institute for Molecular Genetics, Berlin, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Cell Reports
Verified
Journal Article
Open access
KKKaterina Kraft
Katerina Kraft
SGSinje Geuer
Sinje Geuer
AWAnja J. Will
Anja J. Will
WCWing Lee Chan
Wing Lee Chan
CPChristina Paliou
Christina Paliou
GAGuillaume Andrey
Guillaume Andrey
Structural variations (SVs) contribute to the variability of our genome and are often associated with disease. Their study in model systems was hampered until now by labor-intensive genetic targeting procedures and multiple mouse crossing steps. Here we present the use of CRISPR/Cas for the fast (10 weeks) and efficient generation of SVs in mice. We specifically produced deletions, inversions, and also duplications at six different genomic loci ranging from 1.1 kb to 1.6 Mb with efficiencies up to 42%. After PCR-based selection, clones were successfully used to create mice via aggregation. To test the practicability of the method, we reproduced a human 500 kb disease-associated deletion and were able to recapitulate the human phenotype in mice. Furthermore, we evaluated the regulatory potential of a large genomic interval by deleting a 1.5 Mb fragment. The method presented permits rapid in vivo modeling of genomic rearrangements.

27 September 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBjørt K. Kragesteen
Bjørt K. Kragesteen
MSMalte Spielmann
Malte Spielmann
CPChristina Paliou
Christina Paliou
VHVerena Heinrich
Verena Heinrich
RSRobert Schöpflin
Robert Schöpflin
GAGuillaume Andrey
Guillaume Andrey

27 April 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BKBjørt K. Kragesteen
Bjørt K. Kragesteen
AGAmir Giladi
Amir Giladi
EDEyal David
Eyal David
SHShahar Halevi
Shahar Halevi
LGLaufey Geirsdóttir
Laufey Geirsdóttir
IAIdo Amit
Ido Amit

8 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ISIsabelle Schreiber
Isabelle Schreiber
GDGina Dörpholz
Gina Dörpholz
COClaus-Eric Ott
Claus-Eric Ott
BKBjørt Kragesteen
Bjørt Kragesteen
NSNancy Schanze
Nancy Schanze
PKPetra Knaus
Petra Knaus
Insulin-resistance is the main cause of type 2 diabetes. Here we describe the identification and characterization of BMP2 and BMP6 as new insulin-sensitizing growth factors in mature adipocytes. We show that BMP2 and BMP6 lead to enhanced insulin-mediated glucose uptake in both insulin-sensitive and -insensitive adipocytes. We exclude a direct effect of BMP2 or BMP6 on translocation of GLUT4 to the plasma membrane and demonstrate that these BMPs increase GLUT4 protein levels equipotent to Rosiglitazone. BMPs induce expression of PPARγ as the crucial mediator for the insulin-sensitizing effect. A comprehensive RNA-Seq analysis in mature adipocytes revealed regulation of both BMP/Smad and PPARγ target genes. The effects of BMP2 and BMP6 are not completely redundant and include regulation of genes involved in glucose and fatty acid metabolism and adipokine expression. Collectively, these findings suggest the BMP2 and BMP6 pathway(s) as promising new drug targets to treat insulin resistance.

1 June 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
RFRicarda Flöttmann
Ricarda Flöttmann
BKBjørt K. Kragesteen
Bjørt K. Kragesteen
SGSinje Geuer
Sinje Geuer
MSMagdalena Socha
Magdalena Socha
LALila Allou
Lila Allou
MSMalte Spielmann
Malte Spielmann

4 August 2017 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MSMalte Spielmann
Malte Spielmann
LHLuis R Hernandez-Miranda
Luis R Hernandez-Miranda
Isabella CeccheriniIsabella Ceccherini
Isabella Ceccherini
DWDebra E Weese-Mayer
Debra E Weese-Mayer
BKBjørt K Kragesteen
Bjørt K Kragesteen
SMStefan Mundlos
Stefan Mundlos
Background: Congenital central hypoventilation syndrome (CCHS) is a rare life-threatening disorder of respiratory and autonomic regulation. It is classically caused by dominant mutations in the transcription factor PHOX2B. The objective of the present study was to identify the molecular cause of a recessive form of central hypoventilation with autonomic dysfunction. Methods: Here, we used homozygosity mapping and whole-genome sequencing in a consanguineous family with CCHS in combination with functional analyses in CRISPR/Cas9 engineered mice. Results: We report on a consanguineous family with three affected children, all tested PHOX2B mutation negative, presenting with alveolar hypoventilation and symptoms of autonomic dysregulation. Whole-genome sequencing revealed a homozygous frameshift mutation in exon 25 of the MYO1H gene (c.2524_2524delA) segregating with the phenotype in the family. MYO1H encodes for the unconventional myosin IH, which is thought to function as a motor protein in intracellular transport and vesicle trafficking. We show that Myo1h is broadly expressed in the mouse lower medulla, including the CO2-sensitive Phox2b+ retrotrapezoid neurons. To test the pathogenicity of the variant, we engineered two Myo1h mutant mouse strains: the first strain (Myo1h*) resembling the human mutation and the second being a full knock-out (Myo1hFS ). Whole-body plethysmography studies in Myo1h* newborns with the re-engineered human mutation revealed hypoventilation and a blunted response to CO2, recapitulating the breathing phenotype observed in the kindred. Conclusions: Our results identify MYO1H as an important gene in CO2 sensitivity and respiratory control and as the cause of a rare recessive form of congenital central hypoventilation.